FVIIa recombinant NovoSeven
Selected indexed studies
- First 20 years with recombinant FVIIa (NovoSeven). (Haemophilia, 2011) [PMID:20609014]
- Recombinant FVIIa. (Vox Sang, 2004) [PMID:15209873]
- Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents. (Transfus Apher Sci, 2008) [PMID:18267372]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- First 20 years with recombinant FVIIa (NovoSeven). (2011) pubmed
- Recombinant FVIIa. (2004) pubmed
- Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents. (2008) pubmed
- Acquired isolated factor VII deficiency associated with severe bleeding and successful treatment with recombinant FVIIa (NovoSeven). (2004) pubmed
- NovoSeven (recombinant factor VIIa) for the treatment of bleeding episodes and perioperative management in patients with Glanzmann's thrombasthenia. (2014) pubmed
- Factor XI deficiency. (2004) pubmed
- Is recombinant FVIIa the magic bullet in the treatment of major bleeding? (2005) pubmed
- Recombinant factor VIIa (Novoseven) as a hemostatic agent. (2001) pubmed
- Recombinant Activated Factor VII (Eptacog Alfa Activated, NovoSeven®) in Patients with Rare Congenital Bleeding Disorders. A Systematic Review on its Use in Surgical Procedures. (2017) pubmed
- Autoimmune haemophilia. (2008) pubmed